The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...

SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

AbbVie (ABBV) was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s website. Pick the best stocks and maximize your portfolio: Published ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

The candidate, dubbed SIM0500, targets GPRC5D, BCMA and CD3 and is already in phase 1 trials for multiple myeloma in the U.S. and China. It’s not AbbVie’s first foray into T-cell engager ...

(RTTNews) - AbbVie (ABBV) and Simcere Zaiming ... currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma in both China and the U.S. The company explained that SIM0500 ...

is currently undergoing early-stage clinical trials in both China and the U.S. in patients with relapsed or refractory multiple myeloma, a type of blood cancer. AbbVie has been focusing on ...